329.15MMarket Cap-7.95P/E (TTM)
3.745High3.600Low984.77KVolume3.700Open3.690Pre Close3.59MTurnover1.23%Turnover RatioLossP/E (Static)91.18MShares6.23052wk High-7.25P/B290.04MFloat Cap1.84052wk Low--Dividend TTM80.34MShs Float20.696Historical High--Div YieldTTM3.93%Amplitude0.618Historical Low3.648Avg Price1Lot Size
Aquestive Therapeutics Stock Forum
1 min ago
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms Nda Submission Guidance for Anaphylm™ (Epinephrine) Sublingual Film
Doesn't make sense to me?
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints
No comment yet